Archive | Uncategorized RSS feed for this section

Check Out the Digital RESI September 14 – 16 Agenda

25 Jun

By Karen Deyo, Senior Investor Research Analyst, LSN

RESI is continuing to improve our digital events, adding features and content to increase the efficiency of interactions between investors and fundraising company CEOs. While RESI is a partnering-focused conference, the panel and workshop content offer key insights for startup CEOs, helping them avoid common pitfalls when interacting with investors. LSN is pleased to announce our panel lineup for our upcoming Digital RESI, taking place September 14-16. With panels focusing on different sectors and indications, such as Medical Device Investors, Diagnostics Investors, and Oncology Innovation, as well as panels featuring different investor types, such as Health System Partners, Seed Funds, and Impact Investors, startups can find a panel of investors that can provide them with valuable tips to help in their fundraising campaigns. While most of the panels will be prerecorded, attendees will be able to listen in to live sessions during the conference, with the ability to submit questions for Q&A. Make sure to register to gain access to this valuable content.

Hot Investor Mandate: China Investment Firm Deploys Up to $5M in Early-Stage Companies & $50M in Growth-Stage Companies Across Various Life Science Sectors

18 Jun

An investment firm headquartered in China with an additional office in the USA invests exclusively in the life science sector; the firm invests primarily in the USA and China, but will also invest in other regions such as Europe and Canada. Within China, the firm makes growth investments in companies that have existing revenues; in the USA and other regions, the firm makes both venture and growth-equity stage investments in both pre-revenue and revenue-stage companies. The firm’s allocations are highly varied. From the main fund, investments typically range from $15-50 million, though larger investments are of interest as well; the firm has another fund focused on earlier stage companies that actively makes investments of typically $2-5 million, generally in financing rounds of $10 million or less. The firm is open to syndication. The firm is also particularly interested in working with companies that are open to or actively interested in seeking partnerships or opportunities in China.

The firm invests in therapeutics, medical devices, diagnostics, healthcare services, and clinically-oriented healthcare IT, and will consider investing in any indication area or technology subsector; however, orphan indications, dermatology/aesthetics, oncology, and blood diseases are of particular interest in the biopharma space; general surgery, neurovascular, cardiovascular, minimally invasive technologies, women’s health, respiratory care, novel diagnostics and orthopedics are of particular interest in the device space. The fund for earlier stage companies focuses on early stage opportunities in biotech; from the main fund, the firm in most cases makes investments in products that have obtained market approval or are very close to commercialization, but earlier investments may be considered for highly innovative products or products that can demonstrate strong efficacy signals at an earlier stage (such as anti-infectives). For devices and diagnostics, the firm only invests in commercial-stage companies.  Generally, the firm does not invest in imaging.

The firm is flexible regarding management teams, and works with both serial entrepreneurs and entrepreneurs who lack industry experience.  In addition to investing in private companies, the firm is able to invest in public companies by means of PIPEs or public market placements. The firm is interested in investing in companies with products that can demonstrate cost-effectiveness.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Too Many Early Stage Companies Competing for Too Little Dollars

14 May

By Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series

Global early stage investment will be manifesting in unique partnerships and alliances as new business models proliferate.  Though nascent, a new paradigm is evolving around sourcing, vetting, developing, operating, testing, prepping for licensing and exiting of technology assets.  There are 100s of Biotech and Pharma incubators sprouting up, not to mention the proliferation of university, regional, state and national incubator programs worldwide, because technologies are reaching a breakthrough threshold to change the state of patient care and how we treat and cure disease. Big Pharma plus hundreds in the U.S. alone are all in the hunt to find solutions that will impact the healthcare market.

The incubator strategies are all over the map, depending on corporate mandates. I have stated, in the past, that finding seed money (under 2mm) for 1000s of companies is a lot different than finding series A and B capital (10-50mm). The simple math dictates that a funding bottleneck is on the horizon. This is not a scientific survey, but an estimate based on our knowledge of the market. Using the LSN Company Platform, the NIH SBIR/STTR database and the list of RESI attendees over the last 8 years, our ballpark estimate is that there are around 10-15K early stage companies in the life science arena, with the following distribution.

LSN called and Googled around, and estimated that there was around $60B in investor capital in 2019 for early stage healthcare companies. Assuming there will be 10,000 fundraising startups, with 75% raising a Series A at a ballpark $10M+ and 25% raising a Series B at a ballpark $30M+, our back of the envelope, very conservative, calculation is that at least $150B in capital is needed, with only $60B available.

The point here is that there will be a very large bottleneck in cash due to a lot of need and not a lot of available dollars.

The game changer here is that ALL these incubators have to prepare their early stage companies for the up and coming bottleneck.  The incubators have to better manage their assets, and train their early stage firms on how to raise money and secure strategic partnerships, while their portfolio companies need to actively achieve milestones and get compelling data. All RESIs have a 1:1 ratio of companies to investors, giving companies a great platform to make themselves noticed. Even still, many investors say they invest in only about .5% of the companies they see each year. These incubators with 1000s of early stage companies need to worry about how to get their companies to rise above the noise in the marketplace, as too many early stage companies compete for too few dollars!

 

Digital RESI June Speaker Spotlight: Expert Insights from an All-Star Lineup

7 May

By Jessica Yang, Investor Research Analyst, LSN

LSN’s inaugural Digital RESI event in March attracted over 500 attendees and featured over 60 panelists, and we expect a much larger event for June! The Digital RESI June event will feature 11 investor panels that span various investor groups (such as Family Offices and Big Pharma) and industry fields (such as Digital Health and Medical Devices), as well as a new panel, Longevity and Age-Related Disease. All these panels are aimed at providing entrepreneurs with insights and tips about raising capital and acquiring partnerships.

If you’re interested in hearing and meeting active industry experts, register here by May 11th to get your biggest discount!

Here are some of the panelists who will be speaking at Digital RESI June:


Ton Berkien
Director, Business Development
Amgen

Alexandra Bause
Partner
Apollo Health Ventures

David Cruikshank
Partner
ARCH Venture Partners

Chris Haskell
VP, Head of West Coast Innovation Center
Bayer

Travis Whitfill
Partner
Bios Partners

Mark Ralph
Global Head of Contracts and Alliance Management
Boehringer Ingelheim

Debbie Lin
Executive Director – Digital Health
Boehringer Ingelheim Venture Fund

Brent Ahrens
General Partner
Canaan Partners

Marc Lambrechts
Senior Investment Manager
Capricorn Partners

Neil Swami
Principal
Catalyst Health Ventures

Anjan Aralihalli
Venture Partner
CTI Life Sciences Fund

Tim Luker
Sr. Director, Emerging Technology & Innovation, Corporate BD
Eli Lilly & Co

Shaoyu Chang
Vice President
FC Capital

Sherry Grisewood
Senior Investment Officer
FoxHill Asset Management

Bill Hyun
Venture Partner
Genoa Ventures

Juri Bach
Investment Manager
High-Tech Gründerfonds

Wouter Meuleman
Director, Venture Investments
Illumina Ventures

Emilia Gonzalez
Principal
Joyance Partners

Sohaib Siddiqui
Managing Partner
Kettlebeck Ventures

Laura Hong
President
Klus Pharma

Paul Russo
CEO
KYTO Technology & Life Science

David Gordon
Head of Investments
Longliv Ventures

Hakan Goker
Executive Director
M Ventures

Dave Schulte
Managing Director
McKesson Ventures

Randy Berholtz
Senior Advisor
Mesa Verde Venture Partners

Shaan Gandhi
Principal
Northpond Ventures

Bob Saunders
General Partner
OCA Ventures

Diana Saraceni
Founder, Managing Director
Panakes Partners

Sean Cheng
Senior Investment Manager
Philips Health Technology Ventures

Brian Meshkin
Managing Partner
Profound Ventures

Richard Proscia
Senior Associate
Providence Ventures

Alexandra Manick
Associate Principal
Schooner Capital

Sakae Asanuma
President
Taiho Ventures

Nat Brinn
Partner
VC23

Bryan Grulke
Partner
Volcano Capital

Bruce Cohen
Advisor
Xeraya Capital

Terran Biosciences Creates A New Record With 45 Investment Partnering Meetings at Digital RESI – Congratulations

9 Apr

By Bryanna Allison, Business Development Manager, LSN

Sam Clark
CEO of Terran Biosciences

Dustin Tetzl
CBO of Terran Biosciences

Bryanna Allison
BD Manager of LSN

To say that Digital RESI event worked BIG TIME for Terran Biosciences would be an understatement  When LSN gathered up metrics and investor testimonials Terran really stood out. To get an idea of what the secret sauce was I spoke to Sam Clark, CEO, and Dustin Tetzl, CBO, of Terran Biosciences on how they managed to make Digital RESI work so well for them.

Bryanna Allison (BA): It was impressive to see how successful you were with the digital platform! I saw that you managed to book 45 meetings over the three days, correct?

Dustin Tetzl (DT): Yes! 7 of our meetings took place outside of Digital RESI. We woke up early to take meetings, to maximize our availability to global investors.

Sam Clark (SC): We made an effort to reach out to a lot of investors, as we feel we have a unique value proposition to offer them. Our assets are uniquely late-stage, with near-term catalysts, and they address large unmet needs in the CNS space, and we made sure to highlight that.

BA: How many RESIs have you attended?

DT: This was our first RESI introducing our Series A round. We attended one last year for a previous financing round.

BA: Tell me what you thought about Digital RESI in comparison to the on-site RESI you attended last year – what were the advantages and disadvantages?

SC: Well, Digital RESI was certainly more convenient and less expensive – we probably wouldn’t have been able to attend RESI in Paris, as it was originally planned.

DT: However, nothing can truly replace the value of a face-to-face meeting. But for now, everything has to shift to digital and we have to adapt, but a hybrid model of digital and on-site could be the future of events like RESI.

BA: How many meetings did you get at an on-site RESI, in comparison to the digital event?

SC: Well, our company has achieved significant milestones since the last RESI we attended, and this the first real showing of this fundraising round at a RESI event. We had a pretty full schedule previously as well, but the digital format allowed us to stack them up more easily.

BA: What advice would you give to fellow CEOs on how to secure a large number of meetings at Digital RESI events?

SC: There are a multitude of factors. For us, the first priority was presenting a clear value proposition, and then fine-tuning our message and marketing materials. We spent a lot of time combining these effectively into an initial outreach message for investors, which has led to a large increase in investor interest. It’s important to be concise but also comprehensive in your messaging—for us it was about clearly outlining the value of our assets and the unique and near-term ROI potential for investors.

DT: We also spent a good amount of time reaching out to all investors who could be a fit. We followed up with them to secure as many meetings as we could. We have found that RESI provides us with a good way to showcase our assets, make good connections, and get valuable feedback.

BA: Did you find it useful to have partnering spread out over three days?

DT: Yes! If it had been four days of partnering, we might have even filled that one, too, as we had to schedule several meetings over subsequent days.

SC: The 30-minute meetings are just long enough to make an initial impression. It’s a great format and we found it useful for getting enough information across to pique investor interest, while still allowing us to meet with as many investors as possible.

BA: Were the investors responsive on partnering? How important was it for you to follow up?

SC: Many investors accepted the meetings after a single request, but we did need to follow up with some before we got meetings. Overall, the response we received was excellent.

BA: Did you continue reaching out to investors outside of your meetings?

DT: Yes, in large part due to the fact that we ran out of time to meet with investors during the scheduled slots in partnering. We made sure to get their contact information so that we could follow up outside the system and set up meetings.

BA: What are some of the obstacles you are currently facing in your company, in light of COVID-19?

DT: The most obvious challenge is that we can’t meet these investors in person. It’s always preferable when you can meet face-to-face, which allows the investor to get a sense for the team they’re investing in. In our case, our management team members have led multiple successful FDA approvals in the CNS space (including Abilify), and have founded multiple successful biotech companies, so it’s nice to have everyone in the room when possible.

SC: Digital RESI videoconferencing is a good alternative though, and it has helped us keep momentum  even during COVID-19.

BA: So, Digital RESI contributed to your investor pipeline?

SC: Yes! We’re now managing this influx of investor interest. Some groups are making progress quickly, already in the middle of their due-diligence, and they in turn have also brought other potential investors to the table. This RESI conference has certainly helped us expand our reach – thanks!

About Terran Biosciences:

dustintetzl@terranbiosciences.com

Terran is a new biotech company based in NYC developing a uniquely late-stage portfolio of therapeutics and technologies for patients with psychiatric and neurological diseases:

  • Our lead program is TR-01, a phase 2b therapeutic for schizophrenia, with a novel mechanism and robust safety and efficacy already demonstrated in multiple phase 2 studies.
  • Our preclinical asset, TR-36, is backed by promising animal and in vitro data in models of schizophrenia and depression
  • Additionally, we are developing a biomarker software platform that can provide information to aid in the diagnosis and monitoring of schizophrenia, Parkinson’s, and Alzheimer’s disease using standard MRI. This program enhances our own clinical trials, and is well positioned for a near term FDA approval where it could capture the majority of a multi-billion-dollar clinical market.

Our management team members have over 20 FDA approvals in the CNS space and have founded multiple successful biotech companies. We are backed by seed capital from Peter Thiel, Christian Angermayer, and Presight Capital, and are currently raising our Series A.

Life Science Nation & Women In Bio Join Forces to Feature Women In Bio Members at RESI

9 Apr

By Erich White, Business Development Manager, West Coast, LSN

LSN is pleased to announce that Women In Bio will be joining the RESI Conference Series as a Gold Sponsor for both the Digital RESI partnering event on April 29-30, and Digital RESI conference, June 8-10. Women In Bio plays a vital role in the life sciences, ensuring women founders and first time CEOs have the resources and support needed to grow successful bioscience-related businesses, and providing a forum for women to come together to celebrate and support each other’s success. WIB is partnering with LSN to connect women leading early stage life science companies with global investors and strategic partners. WIB will also sponsor a pitch session during the Digital RESI conference in June, featuring 5 WIB-member companies.

Women In Bio – Engage. Educate. Empower.

Women in Bio/WIB is a US non-profit organization founded in 2002 to support and connect women in the life sciences from the classroom to the board room.

We are an organization of professional women from all career walks in the field of life sciences. We are all volunteers and we all share the goal of enabling and empowering women to reach the highest levels of leadership, and — more importantly — to fulfill their own career aspirations.

We belong to biotech and pharma companies, universities and institutes, law and accounting firms, marketing and PR firms, CROs and CMOs.

WIB’s primary focus is to provide women-to-women mentorship and leadership support through all stages of career development

  • from bench to boardroom
  • from academia to industry
  • from first job to last
  • from idea to entrepreneur

With 13 chapters in the US and Canada WIB is committed to fulfill this mission with educational webinars, events, mentoring and networking.

Some of the well-recognized programs are:

Young Women in Bio with STEM education, Executive Women in Bio with the Board Room Ready program.

Many of our members are entrepreneurs, and a focus on entrepreneurship has remained core to WIB’s mission.

With the WIB-Entrepreneur Center we started an entrepreneur focused program dedicated to supporting female founders and first time CEOs from early start-up to later project stages of their life science companies. Besides offering resources, educational webinars as well as mentoring, we engage women founders/CEOs in peer to peer forums and work on the most critical need which is access to capital and corporate partnerships by offering this year in June a Women In Bio sponsored virtual Pitch Challenge in partnership with Life Science Nation (LSN)/RESI.

Announcing Early Stage “Investor Line-Up” For RESI Europe, Paris On March 23rd

30 Jan

By Claire Jeong, Director of Research, Asia BD, LSN

claireAfter finishing off our most successful RESI to date and recovering from JPM week, we are ramping up our preparations for the upcoming RESI Europe Conference, which will be at the Hyatt Regency Paris Étoile on Monday, March 23rd, 2020. We expanded into Europe for the first time last year, and it is super exciting to be able to go to Paris for our second European conference. We look forward to fostering valuable connections and relationships, as well as working with a lot of new companies and investors/strategic partners based in Europe.

We are anticipating over 200 investors to join us at the event from across the globe. Please take advantage of our Super Early Bird Rate by using our €100 discount code SUPEREBEU on our registration here (expires on Sunday, February 2nd). Hope to see you in Paris!

CONFIRMED RESI EUROPE INVESTORS AND STRATEGIC PARTNERS

As of  January 30th, 2020

RESI Europe 2020 Investor Logos 013020

And More…

%d bloggers like this: